Adriana Pedreañez, Yenddy Carrero, Renata Vargas, Juan P Hernandez-Fonseca, Hugo Hernandez-Fonseca, Jesús A Mosquera
{"title":"Role of Gut Microbiota in Dengue.","authors":"Adriana Pedreañez, Yenddy Carrero, Renata Vargas, Juan P Hernandez-Fonseca, Hugo Hernandez-Fonseca, Jesús A Mosquera","doi":"10.1002/rmv.2577","DOIUrl":null,"url":null,"abstract":"<p><p>Dengue is a disease caused by a flavivirus (DENV) and transmitted by the bite of a mosquito, primarily the Aedes aegypti and Aedes albopictus species. Previous studies have demonstrated a relationship between the host gut microbiota and the evolution of dengue. It seems to be a bidirectional relationship, in which the DENV can affect the microbiota by inducing alterations related to intestinal permeability, leading to the release of molecules from microbiota dysbiosis that can influence the evolution of dengue. The role of angiotensin II (Ang II) in the microbiota/dengue relationship is not well understood, but it is known that the renin-angiotensin system (RAS) is present in the intestinal tract and interacts with the gut microbiota. The possible effect of Ang II on the microbiota/Ang II/dengue relationship can be summarised as follows: the presence of Ang II induced hypertension, the increase in angiotensinogen, chymase, and microRNAs during the disease, the induction of vascular dysfunction, the production of trimethylamine N-oxide and the brain/microbiota relationship, all of which are elements present in dengue that could be part of the microbiota/Ang II/dengue interactions. These findings suggest the potential use of Ang II synthesis blockers and the use of AT1 receptor antagonists as therapeutic drugs in dengue.</p>","PeriodicalId":21180,"journal":{"name":"Reviews in Medical Virology","volume":null,"pages":null},"PeriodicalIF":9.0000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Medical Virology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/rmv.2577","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"VIROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Dengue is a disease caused by a flavivirus (DENV) and transmitted by the bite of a mosquito, primarily the Aedes aegypti and Aedes albopictus species. Previous studies have demonstrated a relationship between the host gut microbiota and the evolution of dengue. It seems to be a bidirectional relationship, in which the DENV can affect the microbiota by inducing alterations related to intestinal permeability, leading to the release of molecules from microbiota dysbiosis that can influence the evolution of dengue. The role of angiotensin II (Ang II) in the microbiota/dengue relationship is not well understood, but it is known that the renin-angiotensin system (RAS) is present in the intestinal tract and interacts with the gut microbiota. The possible effect of Ang II on the microbiota/Ang II/dengue relationship can be summarised as follows: the presence of Ang II induced hypertension, the increase in angiotensinogen, chymase, and microRNAs during the disease, the induction of vascular dysfunction, the production of trimethylamine N-oxide and the brain/microbiota relationship, all of which are elements present in dengue that could be part of the microbiota/Ang II/dengue interactions. These findings suggest the potential use of Ang II synthesis blockers and the use of AT1 receptor antagonists as therapeutic drugs in dengue.
登革热是一种由黄病毒(DENV)引起的疾病,通过蚊子(主要是埃及伊蚊和白纹伊蚊)叮咬传播。以往的研究表明,宿主肠道微生物群与登革热的进化之间存在关系。这似乎是一种双向关系,登革热病毒可通过诱导与肠道通透性有关的改变来影响微生物群,从而导致微生物群失调释放出分子,这些分子可影响登革热的进化。血管紧张素 II(Ang II)在微生物群/登革热关系中的作用尚不十分清楚,但已知肾素-血管紧张素系统(RAS)存在于肠道中,并与肠道微生物群相互作用。Ang II 对微生物群/Ang II/登革热关系的可能影响可归纳如下:Ang II 诱导的高血压的存在,疾病期间血管紧张素原、糜蛋白酶和微核糖核酸的增加,血管功能障碍的诱导,三甲胺 N-氧化物的产生以及大脑/微生物群的关系,所有这些都是登革热中存在的元素,可能是微生物群/Ang II/登革热相互作用的一部分。这些研究结果表明,Ang II 合成阻断剂和 AT1 受体拮抗剂可能被用作登革热的治疗药物。
期刊介绍:
Reviews in Medical Virology aims to provide articles reviewing conceptual or technological advances in diverse areas of virology. The journal covers topics such as molecular biology, cell biology, replication, pathogenesis, immunology, immunization, epidemiology, diagnosis, treatment of viruses of medical importance, and COVID-19 research. The journal has an Impact Factor of 6.989 for the year 2020.
The readership of the journal includes clinicians, virologists, medical microbiologists, molecular biologists, infectious disease specialists, and immunologists. Reviews in Medical Virology is indexed and abstracted in databases such as CABI, Abstracts in Anthropology, ProQuest, Embase, MEDLINE/PubMed, ProQuest Central K-494, SCOPUS, and Web of Science et,al.